Summary Autocrine growth factor secretion has classically been considered as a mechanism by which tumour cells achieve autonomous growth. However, there is now considerable evidence that autocrine circuits operate in the growth regulation of normal adult tissues. Here we consider the possible advantages to the normal epithehal cell of utilising such an external growth factor circuit and suggest that autocrine growth factor secretion, when viewed in a multicellular context, could paradoxically form part of a mechanism for preventing tumour development.
Background
The autocrine hypothesis of growth regulation was first proposed to account for growth factor independence in tumours (Sporn and Todaro. 1980) , and much evidence has accumulated to support this idea (Sporn and Roberts, 1985; Cross and Dexter, 1991; Daughaday and Deuel, 1991) . Indeed, it is now realised that the original concept was too restnrctive and that autocrine circuits also function as a component of normal growth-regulatory mechanisms in many adult tissue types. in which the primary mitogen appears to induce local autocrine production of a cooperating non-tissue-specific secondary mitogen (Coffey. 1987; Bortz et al.. 1988; Cross and Dexter, 1991; Daughaday and Deuel, 1991) . However, while there is an obvious selective growth advantage to a tumour cell secreting its own growth factors, the functional benefits to normal cells are less apparent. Our studies into the role of one of the major locally produced autocrine agents. insulin-like growth factor I (IGF-I), in normal and neoplastic thyroid growth has led us to critically re-examine the classical view of autocrine stimulation as it relates to the single cell and propose an extension of the hypothesis which takes into account growth regulation in a multicellular con- text.
Aside from a weak insulin-like anabolic effect, the major physiological action of IGF-I appears to be as a regulator of cell proliferation in both epithelial and mesenchymal tissues. In this role it acts as a powerful, but relatively non-tissuespecific, 'permissive' mitogen which is required for a maximal proliferative response to more highly tissue-specific trophic factors such as platelet-denrved growth factor (PDGF), fibroblast growth factor (FGF) or thyroid-stimulating hormone (TSH). In cell kinetic terms it fulfils the function of a general progression factor' for cells previously stimulated by a more specific 'competence' factor (Leof et al., 1982) . Although the liver is a major site of synthesis for systemically circulating IGF-I. there is also significant local production of the growth factor by both epithelial and stromal elements (D'Ercole et al., 1984; Han et al., 1987; Hansson et al., 1988) . In particular, many tissue-specific hormones, such as oestrogens.
adrenocorticotrophic hormone (ACTH), luteinising hormone (LH). follicle-stimulating hormone (FSH) and TSH appear to induce or modulate local IGF-I expression in their target tissues in addition to their direct actions (Holly and Wass. 1989 : Sara and Hall. 1990 : LeRoith and Roberts. 1991 (Tode et al., 1989; Yashiro et al., 1989) , as well as requiring a minimum level of IGF-I for mitogenic response in vitro to TSH (Tramontano et al., 1986; Williams et al., 1988) . Further studies have demonstrated that TSH stimulates IGF-I secretion (Tode et al., 1989) and reduces specific IGF-Ibinding protein (Wang et al., 1990) , both of which would be predicted to increase local free IGF-I concentration. Together these data suggest that IGF-I plays a key physiological role in synergising with the TSH stimulus to promote thyrocyte growth and that part of this mechanism involves the induction of an IGF-I autocrine circuit by TSH in the target tissue. Furthermore, there is compelling evidence that aberrant production of IGF-I is involved in the genesis of thyroid tumours (follicular adenomas), in many cases as a result of the oncogenic activation of the ras family of signal transduction proteins (Lemoine et al., 1989; Suarez et al., 1990; Dawson et al., 1995) . These finding are in accordance with a general shift in emphasis over recent years, from an endocrine to a paracrine or autocrine role for IGF-I in growth regulation.
What are the advantages of an autocrne circut?
In evolutionary terms, the relatively non-tissue-specific mitogenic action of IGF-I suggests that it formed part of a primordial mechanism upon which higher orders of control have been successively grafted to provide independent regulation of specialised tissue types. One possible reason for retaining this primitive system is that it allows for integration of multiple mitogenic signals. such that a combination of tissue-specific primary factors can stimulate cell growth by acting through a common final pathway -the locally produced mitogen. Teleologically however, it seems unnecessary for such a mechanism to involve an external loop. since signal integration could equally well be served by convergence of the signalling pathways at an intracellular level. 'Exteriorisation' is 'costly' in terms of the high production levels of growth factor required to overcome diffusion effects and the need to maintain an additional receptor pathway. so that, with regard to the individual normal cell, the classical autocrine mechanism seems to offer little overall benefit. The evolutionary advantage of such a system must therefore preIs au rhine g h fdactor seaetion prie? T Dawson and D Wynford-Thomas sumably lie in the element of cell-cell communication which it affords, implying that it has evolved not so much for autocrine but for paracrine stimulation.
One important aspect of this is, undoubtedly. that production of a non-specific mitogen. such as IGF-1, by growing epithelial cells may stimulate associated stromal elements not otherwise influenced by the primary signal, thereby providing for coordinated growth of the tissue. However, if this were the only raison detre for an exteriorised signal, why should epithelial cells produce a growth factor which is also autostimulatory. rather than an agent more specific for the stromal component? The answer may be that paracrine control by IGF-I operates not just in the conventional heterotypic role, to coordinate stroma with epithelium, but also in a homotypic mode, to coordinate growth within the epithelium itself. The essential tenet of this 'homotypic paracrine hypothesis is that the concentration of IGF-I to which an epithelial cell is exposed depends not only on its own autocrine secretion but also on that of its neighbours. such that the critical concentration required for response to its tissuespecific mitogen cannot be achieved by a single cell but requires the cooperative secretory activity of the epithelial population en masse.
Classical Ps cooperative autocrine circuits
Autocrine circuits have conventionally been considered in terms of the individual cell in isolation. In vivo however, the steady-state extracellular concentration of an autocrinederived growth factor to which any given cell in a tissue is exposed may be expected to depend not only on its own secretion rate but also on that of its immediate neighbours. The extent of this influence will be dictated by the effective range of the factor in the tissue, determined, inter alia. by the rate of diffusion through the extracellular fluid (ECF) and the rate of inactivation (through proteolysis and sequestration by soluble and matrix-bound binding proteins). This is of course difficult to assess expenrmentally, but since it is generally accepted that significant paracrine IGF-I communication operates between stroma and epithelium. it seems reasonable to infer that a significant paracrine contribution also exists between neighbouring epithelial cells. We propose that such cooperation is in fact essential to allow the IGF-I concentration in the ECF to reach the required threshold to permit a mitogenic response to the primary mitogenic signal ,e.g. TSH).
Paracrine signalling is undoubtedly the key to explaining the evolutionary benefit of an extracellular loop in the mitogenic response since it adds a tissue-level dimension which is not afforded by a purely intracellular signalling pathway. Although the original selective pressure for evolution of paracrine control may have been its heterotypic role, we argue that homotypic regulation provides major additional advantages through its inherent 'smoothing' effect on (1958, 1970) . However, the underlying mechanisms of promotion have remained controversial. A popular explanation is that the initiating mutation is insufficient by itself to induce growth in the presence of normal levels of primary mitogen. but if clonal expansion occurs under the influence of a physiological stimulus, further mutations occur which allow eventual autonomy. Alternatively. it has been suggested that mutation marginally increases cellular sensitivity to the primary mitogen. thereby providing a selective growth advantage in states of physiological stimulation. The homotypic paracrine hypothesis, however, provides a novel explanation for this phenomenon. in which tumour promotion is seen to be simply an innate consequence of cooperative autocrine control.
This may be explained in the following manner. During physiological growth. part of the response of the normal cell to the primary mitogen (e.g. TSH) involves induction of a secondary mitogen, such as IGF-I, in an autocrine loop (Figure 1 ). Tumour cells, however, appear to express this autocrine loop independent of primary mitogen stimulation or at least independent of any increase in mitogen concentration above normal basal levels (Figure 1 ). This is supported by work from our own and other laboratories which have demonstrated increased IGF-I secretion by tumour cells com- (reviewed by Macauley, 1992) . This aberrant secretion, though. does not appear to be due to any primary abnormality of the IGF-I gene itself but represents an appropriate response to inappropriate constitutive activation of intracellular signalling molecules. such as ras. which mimic the effect of an increase in concentration of the primary mitogen.
According to the classical autocrine hypothesis. aberrant secretion of the secondary mitogen should provide the selective advantage required to allow the mutant cell to grow autonomously and form a tumour (Figure 2c ). This, however, does not explain the phenomenon of tumour promotion by a physiological growth stimulus as described above. We propose instead that proliferation of a single mutant cell is frustrated since, even though its own IGF-I production is elevated, it cannot achieve the required mitogenic threshold concentration in isolation against the dilutional effects of the surrounding milieu populated by quiescent low-output normal cells (Figure 2c and 3a) . Tumour development is therefore effectively suppressed. However, if a period of physiological growth occurs. clonal expansion of the mutant cell will be supported by the cooperative secretory activity of neighbouring normal cells (Figure 3b ). Eventually the mutant clone will reach a 'critical mass' whereupon it can generate sufficient IGF-I concentration in its microenvironment to sustain autonomous growth without the cooperation of adjacent mitogen-stimulated normal cells (Figure 3c) . Thus, the tumour will be able to continue to grow even after the primary mitogenic stimulus has returned to basal levels.
In this model therefore, the promoter is seen to play no direct signalling role but merely alters the clonal composition of the tissue, thereby circumventing homotypic paracrine control. Promotion as an inherent consequence of expansion of tumour mass could of course also operate by the reciprocal model, originally proposed by Wheldon (1975) , in which tumour cells fail to secrete an inhibitory paracnrne factor, the concentration of which therefore declines as the centre of the clone becomes progressively further from the normal surrounding cells. As yet, however. no good candidate effectors for such a model have been identified.
In addition to providing an explanation for the very low yield of experimental thyroid tumours in the absence of primary mitogen stimulation. this hypothesis also accounts for the well-documented higher incidence of human thyroid tumours in iodine-deficient goitrous areas of the World (Shi et al., 1991) . Presumably those tumours which rise without any apparent preceding hyperplasia are the result of rare oncogenic events which either bypass the requirement for IGF-I or raise output to a level above the maximum achievable by trophic hormone stimulation, which is then sufficient to circumvent the limitation normally imposed by homotypic paracrine control.
ConclusioIs
We propose that, while the classical hypothesis of autocrine growth factor secretion was originally elaborated in relation to the malignant transformation of cells. autocrine circuits actually form part of a mechanism which coordinates tissue growth in response to the primary mitogen and paradoxically limits the development of neoplastic clones. This hypothesis fits all existing data and provides a cogent explanation for the hitherto poorly explained phenomenon of tumour promotion by physiological growth stimulation. Although formulated in relation to the thyroid model. we can see no reason why this mechanism should not have evolved to perform a similar function in other tissues where autocnrne circuits form part of normal growth regulation. 
